Evidence map›Paper›PMID 25001269›Full record

Trial reportHypertension (Dallas, Tex. : 1979)2014

Autonomic blockade improves insulin sensitivity in obese subjects.

Alfredo Gamboa, Luis E Okamoto, Amy C Arnold, Rocio A Figueroa, André Diedrich, Satish R Raj, Sachin Y Paranjape, Ginnie Farley, Naji Abumrad, Italo Biaggioni

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Hypertension (Dallas, Tex. : 1979), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Carotid body denervation improves hyperglycemia in obese mice.Journal of applied physiology (Bethesda, Md. : 1985) · 2024
    Article
  8. Adrenoceptors and Hypertension.Handbook of experimental pharmacology · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. How Western Diet And Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alfredo GamboaFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Luis E OkamotoFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Amy C ArnoldFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Rocio A FigueroaFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
André DiedrichFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Satish R RajFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Sachin Y ParanjapeFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Ginnie FarleyFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Naji AbumradFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN.
Italo BiaggioniFrom the Division of Clinical Pharmacology, Departments of Medicine (A.G., L.E.O., A.C.A., R.A.F., A.D., S.R.R., S.Y.P., G.F., I.B.), Pharmacology (S.R.R., I.B.), Biomedical Engineering (A.D.), and Surgery (N.A.), Vanderbilt University, Nashville, TN. italo.biaggioni@vanderbilt.edu.
Anna Needs Neuroblastoma Answers · US

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Structural genomics of norepinephrine transportersP01HL056693 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROBERTSON, DAVID HERLIE · 1997 to 2016
$30.8M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI ELASY, TOM A · 1986 to 2011
$28.1M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4M
Training CoreU54NS065736 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FREEMAN, ROY · 2009 to 2018
$11.6M
RYGB Improves Metabolism by Interrupting the Gastric Adipose Tissue AxisR01DK091748 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ABUMRAD, NAJI N · 2011 to 2015
$3.0M
Sympathetic Nervous System and Nitric Oxide in Obesity Associated HypertensionK23HL095905 · NHLBI · VANDERBILT UNIVERSITY · PI GAMBOA, ALFREDO · 2010 to 2014
$754k
NCATS NIH HHS UL1 TR000445NHLBI NIH HHS K23 HL095905NHLBI NIH HHS K23 HL-95905NHLBI NIH HHS P01 HL056693NIDDK NIH HHS DK 020593NIDDK NIH HHS DK20593NIDDK NIH HHS P30 DK020593NIDDK NIH HHS R01 DK091748NIGMS NIH HHS T32 GM007569NINDS NIH HHS U54 NS065736
6 · The paper itself

Abstract

Obesity is an important risk factor for the development of insulin resistance. Initial compensatory mechanisms include an increase in insulin levels, which are thought to induce sympathetic activation in an attempt to restore energy balance. We have previously shown, however, that sympathetic activity has no beneficial effect on resting energy expenditure in obesity. On the contrary, we hypothesize that sympathetic activation contributes to insulin resistance. To test this hypothesis, we determined insulin sensitivity using a standard hyperinsulinemic euglycemic clamp protocol in obese subjects randomly assigned in a crossover design 1 month apart to receive saline (intact day) or trimetaphan (4 mg/min IV, autonomic blocked day). Whole-body glucose uptake (MBW in mg/kg per minute) was used as index of maximal muscle glucose use. During autonomic blockade, we clamped blood pressure with a concomitant titrated intravenous infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. Of the 21 obese subjects (43±2 years; 35±2 kg/m(2) body mass index) studied, 14 were insulin resistant; they were more obese, had higher plasma glucose and insulin, and had higher muscle sympathetic nerve activity (23.3±1.5 versus 17.2±2.1 burst/min; P=0.03) when compared with insulin-sensitive subjects. Glucose use improved during autonomic blockade in insulin-resistant subjects (MBW 3.8±0.3 blocked versus 3.1±0.3 mg/kg per minute intact; P=0.025), with no effect in the insulin-sensitive group. These findings support the concept that sympathetic activation contributes to insulin resistance in obesity and may result in a feedback loop whereby the compensatory increase in insulin levels contributes to greater sympathetic activation.

Indexed as

AdultAutonomic Nervous SystemBlood GlucoseBlood PressureCross-Over StudiesEnzyme InhibitorsFemaleGanglionic BlockersGlucose Clamp TechniqueHumansInsulinInsulin ResistanceMaleMiddle AgedMusclesNitric Oxide SynthaseBlood GlucoseEnzyme InhibitorsGanglionic BlockersInsulinNitric Oxide Synthaseomega-N-MethylarginineTrimethaphanautonomic nervous systeminsulin resistanceobesity

Identifiers

PMID25001269
PMCPMC4162826
OpenAlexW2136038391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.